HAVCR2 and cancer: Based on the expression of TIM-3 in TME and its suppressive effect on adaptive immune cells, it can be suggested that blocking PD-1, which is used as an immunotherapy for a few cancers, may not have a sufficient effect in contrast to blocking PD-1 and TIM-3 together (Table 1).